Compound Evidence File
#EC-2026-0895
Vesugen
Filed under Peptides. The bureau holds 170 laboratory returns for this compound from 58 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
58 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 2 Feb 2026 | 12 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Feb 2026 | 19 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Nov 2025 | 21 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 22 Mar 2026 | 9 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 10.0 | 10.0 | 13 Jun 2026 | 19 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Apr 2026 | 16 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Dec 2025 | 21 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Feb 2026 | 12 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 10.0 | 10.0 | 4 May 2026 | 12 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Jan 2026 | 6 Jan 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 11 May 2026 | 4 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Mar 2026 | 5 Mar 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 10.0 | 10.0 | 10.0 | 2 Apr 2025 | 2 Apr 2025 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Apr 2026 | 1 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Dec 2025 | 7 May 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Dec 2025 | 3 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 10.0 | 12 May 2026 | 24 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Jun 2026 | 6 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 22 Jan 2026 | 22 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 11 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 15 May 2026 | 7 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Apr 2026 | 5 Jul 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 9.8 | 9.8 | 9.8 | 16 Mar 2025 | 16 Mar 2025 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 9.8 | 9.8 | 9.8 | 2 Apr 2025 | 2 Apr 2025 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 9.7 | 9.7 | 9.7 | 16 Mar 2025 | 16 Mar 2025 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 9.5 | 9.5 | 9.5 | 3 Jun 2025 | 3 Jun 2025 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 9.2 | 9.2 | 9.2 | 2 Jul 2025 | 2 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 9.1 | 8.1 | 10.0 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.8 | 7.5 | 10.0 | 23 May 2026 | 23 May 2026 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 8.8 | 8.8 | 8.8 | 3 Jul 2025 | 3 Jul 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.7 | 7.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.7 | 6.9 | 9.4 | 21 May 2026 | 21 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.7 | 7.8 | 9.5 | 25 May 2026 | 25 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 2 | 8.4 | 6.9 | 9.8 | 13 Jun 2025 | 19 Jan 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 6 | 8.3 | 6.6 | 10.0 | 2 Jul 2025 | 25 May 2026 |
| Planet PeptideCASE #VI-2026-0092 | X | 2 | 7.8 | 6.5 | 9.2 | 2 Jul 2025 | 24 May 2026 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 7.8 | 7.8 | 7.8 | 7 May 2025 | 7 May 2025 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 2 | 7.7 | 6.9 | 8.4 | 3 Jun 2025 | 25 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 3 | 7.6 | 6.6 | 8.5 | 16 Mar 2025 | 25 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Apr 2025 | 2 Apr 2025 |
| M-PeptidesCASE #VI-2026-0442 | X | 1 | 7.4 | 7.4 | 7.4 | 2 Jul 2025 | 2 Jul 2025 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 8 | 7.3 | 5.1 | 9.9 | 25 Apr 2025 | 19 Jan 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 7.3 | 7.3 | 7.3 | 16 Mar 2025 | 16 Mar 2025 |
| Peptide CraftersCASE #VI-2026-0994 | X | 3 | 6.7 | 6.0 | 7.4 | 2 Jul 2025 | 25 May 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 6.7 | 6.4 | 6.9 | 28 Mar 2025 | 17 May 2026 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 6.5 | 6.5 | 6.5 | 17 Dec 2024 | 17 Dec 2024 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 6.4 | 6.4 | 6.4 | 7 May 2025 | 7 May 2025 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 2 | 6.3 | 5.6 | 7.1 | 17 Dec 2024 | 25 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 6.2 | 6.2 | 6.2 | 6 May 2025 | 6 May 2025 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 5.6 | 4.5 | 6.8 | 7 May 2025 | 24 May 2026 |
| Astro PeptidesCASE #VI-2026-0424 | X | 2 | 5.6 | 5.6 | 5.6 | 27 Feb 2025 | 20 May 2026 |
| Loti LabsCASE #VI-2026-0171 | X | 3 | 5.2 | 4.5 | 5.8 | 3 Jul 2025 | 25 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 4.4 | 4.4 | 4.4 | 17 Dec 2024 | 17 Dec 2024 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 1.4 | 1.1 | 1.6 | 3 Jul 2025 | 26 Jan 2026 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.0 | 0.0 | 0.0 | 20 Jun 2025 | 20 Jun 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Vesugen alone.